🧑‍⚕️ Pfizer recently announced that a clinical trial of its drug Ibrance hasn't worked out as a long-term treatment for breast cancer. This news is unfortunate on a few levels, but specifically, in terms of price, the impact isn't great. Upon releasing the news PFE dumped as analyst began to revise earnings expectations downward. This sell-off caused a reversal of the shorter term post-COVID downtrend and caused what appears to be a return to the pre-COVID downtrend. While we do think a short setup makes sense here given the facts, there is plenty of reason to be bullish from a longer-term point of view given Pfizer's projection that it could have a COVID vaccine by fall and given their funding of other COVID companies working on treatments.
✨ Drop a comment asking for an update, we do NEW setups every day! ✨ Like, Comment & Follow to help the community grow 🎉🎉
---
1. Fractal Trend is showing a fresh downtrend (Maroon colored bars) on the 1-hour timeframe.
2. With this strategy, we are looking for short setups in an downtrend and as such want to enter short on retests of bearish order blocks plotted by Orderblock Mapping (Maroon colored lines) and/or bearish S/R levels plotted by Directional Bias (Maroon colored lines).
3. The play here is simple, we are looking for a reaction at the R1 S/R flip and then are targeting the S1 orderblock at the current low. Then, by placing a stop just above the S/R flip, we have ourselves a solid 4.09 risk/reward ratio.
4. Other levels to the upside to watch here are R2 and R3 bearish orderblocks which should see a reaction if and when we move to the upside.
5. Below, the S2 and S3 bullish orderblocks should provide support if we move to the downside.
Keep in mind we are only looking to short weakness in the near term here, as time goes on PFE should find support and potential COVID cures could easily send this stock back up.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.